BCMA-Targeting CAR T-Cell Therapy Effective in R/R Myeloma?

A phase I study examines the use of LCAR-B38M, a CAR T-cell therapy directed against BCMA, in patients with relapsed/refractory multiple myeloma.

Source: CancerNetwork - January 24, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news